LEADER 02238nam  2200481   450 
001 9910774608003321
005 20170701144453.0
010   $a1-78262-985-8
035   $a(CKB)3710000001055705
035   $a(MiAaPQ)EBC4803359
035   $a(oapen)https://directory.doabooks.org/handle/20.500.12854/70699
035   $a(EXLCZ)993710000001055705
100   $a20170226h20172017  uy             0
101 0 $aeng
135   $aurcnu||||||||
181   $2rdacontent
182   $2rdamedia
183   $2rdacarrier
200 00$aAnti-aging drugs $efrom basic research to clinical practice /$fedited by Alexander Vaiserman
210   $aCambridge$cRoyal Society of Chemistry$d2017
210  1$a[Cambridge, England] :$cRoyal Society of Chemistry,$d2017.
210  4$dİ2017
215   $a1 online resource (592 pages) $cillustrations, tables
311   $a1-78262-435-X 
311   $a1-78262-660-3 
320   $aIncludes bibliographical references at the end of each chapters and index.
330   $aProvides an overview of current research aimed to search for life-extending medications and describes pharmacological aspects of anti-aging medicine. Readers are introduced to the historical background of geroprotection in the first chapter. In-depth information on models for investigating geroprotective drugs precedes a section covering anti-aging properties of pharmaceutical compounds, such as calorie restriction mimetics, autophagy inducers, senolytics and mitochondrial antioxidants. Finally, strategies to translate discoveries from aging research into drugs and healthcare policy perspectives on anti-ageing medicine are provided to give a complete picture of the field.--$cSource other than Library of Congress.
606   $aDrug development
606   $aAging$xPrevention
610   $aaging; disease
615  0$aDrug development.
615  0$aAging$xPrevention.
676   $a615.19
700   $aJanac$b Sarah$4edt$01461188
702   $aVaiserman$b Alexander
712 02$aRoyal Society of Chemistry (Great Britain),
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910774608003321
996   $aAnti-aging drugs$93664857
997   $aUNINA